TMS for the Treatment of Pancreatic Cancer Pain
Completed · Not applicable · Has a placebo group
Conditions studied: Pain, Visceral Pain, Pancreatic Cancer
In brief
This is a phase II study that aims to investigate prospectively a new therapy for a cohort of patients with chronic pain attributed to pancreatic cancer. The justification of this study is that the pain is the most important factor for the quality of life of these patients and rTMS has been shown to be significantly associated with pain improvement in patients with abdominal pain due to chronic pancreatitis. This therapeutic trial will be a 10-day, randomized, parallel-group design, double-blind, incomplete cross-over, placebo controlled clinical trial conducted at Beth Israel Deaconess Medical Center. The principal aim of this investigation is the study of pain after a therapeutic intervention. The primary outcome is pain reduction indexed by pain reduction and or analgesic intake reduction. The second aim of the study is to assess the safety this new treatment in patients with pancreatic cancer. The third aim of this study is to investigate whether rTMS treatment is associated with a change in the activity of right secondary somatosensory cortex using magnetic resonance spectroscopy. Because patients with locally advanced or advanced pancreatic cancer often require increasing doses of narcotic pain medications, such as morphine, oxycodone and fentanyl, in order to control their pain, adverse side effects are frequent observed in this population of patients. Therefore rTMS treatment might represent a new therapeutic approach that might be useful not only for pancreatic cancer but also to other types of cancer.
Key facts
- Study ID
- NCT00324428
- Run by
- Beth Israel Deaconess Medical Center
- People needed
- 3
- Starts
- 2006-05-01
- Expected to finish
- 2011-11-01
- Last updated by the study team
- 2017-03-21
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Locally advanced or metastatic pancreatic cancer
- Abdominal pain attributable to pancreatic cancer that requires daily narcotic use
- Stable narcotic dosage the week before study entry
- A computed tomography of the abdomen within four weeks of study entry
- CA19-9 within four weeks of study entry
- ECOG Performance status >=3
You may not qualify if…
- Known brain metastasis
- Patients with major depression with suicidal risk
- Prior neurosurgical procedures
- History of epilepsy
- Previous head injury
- History of Stroke
- Abnormal neurological examination other than as signs of the condition studied in the present protocol
- Contraindication to TMS:
- Implanted pacemaker;Medication pump;Vagal stimulator;Deep brain stimulator;Metallic hardware in the head or scalp: shrapnel, surgical clips, or fragments from welding;Signs of increased intracranial pressure
- TENS unit and ventriculo-peritoneal shunt
- Pregnancy
- Unable to undergo a brain MR
- claustrophobia refractory to anxiolytics
- ferromagnetic metal in the body such as a prosthetic heart valve, a pacemaker, or a brain aneurysm clip).
Where it is running
- Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.